STOCK TITAN
  1. Home
  2. News
  3. AZN

AstraZeneca PLC - AZN STOCK NEWS

Welcome to our dedicated page for AstraZeneca PLC news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca PLC stock.

AstraZeneca PLC (AZN) is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. Formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK, AstraZeneca is known for its extensive research and development in the field of pharmaceuticals and biotechnology.

The company operates globally and generates a significant portion of its revenue from international markets, with the United States accounting for nearly one-third of its sales. AstraZeneca’s product portfolio includes a wide range of branded drugs across several major therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Recent achievements include a global license agreement with Nona Biosciences to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology. The agreement could potentially bring Nona Biosciences up to $575 million upon achieving specified milestones, as well as tiered royalty payments on net sales. AstraZeneca continues to lead in the development of tumor-targeted therapies using cutting-edge technology.

Another noteworthy development is AstraZeneca's collaboration with AbelZeta Pharma to co-develop C-CAR031, a GPC3-targeted CAR-T therapy for treating hepatocellular carcinoma (HCC). The initial clinical results presented at the 2024 ASCO Annual Meeting showed promising safety and efficacy data.

Moreover, AstraZeneca has entered into a significant agreement with Compugen Ltd. to develop rilvegostomig, a PD-1/TIGIT bispecific antibody currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer. This partnership underscores AstraZeneca’s commitment to advancing innovative cancer therapies through strategic collaborations.

With its industry-leading capabilities, AstraZeneca is well-positioned to continue making significant strides in healthcare, providing effective treatments for a variety of diseases and maintaining its reputation as a global leader in pharmaceuticals and biotechnology.

News

ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial

Rhea-AI Summary
ENHERTU shows strong and durable tumor responses in patients with HER2 mutant non-small cell lung cancer. Objective response rates of 49% and 56% were observed with 5.4 mg/kg and 6.4 mg/kg doses, respectively. Median progression-free survival was 9.9 months at 5.4 mg/kg and 15.4 months at 6.4 mg/kg. Favorable safety profile supports the use of ENHERTU. No new safety signals identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
clinical trial
-
News

Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial

Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan shows positive initial results in lung cancer trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers

Rhea-AI Summary
ENHERTU (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive solid tumors and metastatic colorectal cancer. ENHERTU is jointly developed by Daiichi Sankyo and AstraZeneca. HER2 overexpression has been observed in 1% to 28% of metastatic solid tumors and in up to 5% of colorectal cancer patients. The BTDs are recognition of the potential of ENHERTU in these tumor types. ENHERTU has received a total of seven BTDs and has shown promising results in various trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
News

AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients

Rhea-AI Summary
AstraZeneca challenges drug price negotiation provisions of the Inflation Reduction Act (IRA) to protect access to medicines for rare diseases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
none
-
News

AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030

Rhea-AI Summary
AstraZeneca presents data at the WCLC 2023 conference, showcasing the strength of its lung cancer portfolio. The FLAURA2 trial demonstrates the efficacy of TAGRISSO in combination with chemotherapy for EGFR-mutated lung cancer. ENHERTU, IMFINZI, and datopotamab deruxtecan also show promise in addressing unmet needs. AstraZeneca aims to have the right medicine for over half of lung cancer patients by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
News

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial

Rhea-AI Summary
High-level results from the primary analysis of the DESTINY-PanTumor02 Phase II trial showed that ENHERTU demonstrated clinically meaningful progression-free survival and overall survival in previously treated patients with HER2-expressing advanced solid tumors. The trial also showed durable responses and reinforced results from an interim analysis presented at the ASCO Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
clinical trial
News

ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Rhea-AI Summary
Topline results from the ongoing DESTINY-PanTumor02 phase 2 trial show that ENHERTU demonstrated clinically meaningful progression-free survival and overall survival in previously treated patients with HER2 expressing advanced solid tumors. The trial also showed durable responses and confirmed objective response rate. ENHERTU is a jointly developed drug by Daiichi Sankyo and AstraZeneca.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
clinical trial
-
News

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.83%
Tags
clinical trial
-
News

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
clinical trial
News

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none

FAQ

What is the current stock price of AstraZeneca PLC (AZN)?

The current stock price of AstraZeneca PLC (AZN) is $67.01 as of January 10, 2025.

What is the market cap of AstraZeneca PLC (AZN)?

The market cap of AstraZeneca PLC (AZN) is approximately 207.8B.

What is AstraZeneca PLC?

AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. It is headquartered in Cambridge, England.

What therapeutic areas does AstraZeneca focus on?

AstraZeneca’s product portfolio includes drugs across several therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Where does AstraZeneca generate most of its revenue?

A significant portion of AstraZeneca’s revenue comes from international markets, with the United States accounting for nearly one-third of its sales.

What is the recent collaboration between AstraZeneca and Nona Biosciences about?

AstraZeneca and Nona Biosciences have entered into a global license agreement to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology.

What is C-CAR031?

C-CAR031 is a GPC3-targeted CAR-T therapy developed by AstraZeneca and AbelZeta Pharma for treating hepatocellular carcinoma (HCC). Initial clinical results have shown promising safety and efficacy data.

What is rilvegostomig?

Rilvegostomig is a PD-1/TIGIT bispecific antibody developed by AstraZeneca in collaboration with Compugen Ltd. It is currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer.

What are some of AstraZeneca’s key recent achievements?

Recent achievements include a global license agreement with Nona Biosciences for oncology therapies, collaboration with AbelZeta Pharma on C-CAR031, and partnership with Compugen Ltd. for developing rilvegostomig.

Where is AstraZeneca headquartered?

AstraZeneca is headquartered at the Cambridge Biomedical Campus in Cambridge, England.

When was AstraZeneca formed?

AstraZeneca was formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK.

What is the focus of AstraZeneca’s research and development?

AstraZeneca focuses on research and development in pharmaceuticals and biotechnology, particularly in creating treatments for various major therapeutic areas including cancer, respiratory diseases, cardiovascular conditions, and more.
Stock AZN logo
AstraZeneca PLC

Nasdaq:AZN

AZN Rankings

#40 Ranked by Market Cap
#1616 Ranked by Dividends

AZN Stock Data

207.80B
3.10B
0.01%
16.77%
0.32%
Drug Manufacturers - General
Healthcare
Link
United States of America
Cambridge